NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose.
Latest Information Update: 25 Jul 2022
Price :
$35 *
At a glance
- Drugs NGR-TNF (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AGC Biologics
- 05 May 2008 The actual number of patients enrolled was 16.
- 05 May 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
- 06 Feb 2007 New trial record.